Eyer, P.P.EyerHagedorn, I.I.HagedornKlimmek, R.R.KlimmekLippstreu, P.P.LippstreuLöffler, M.M.LöfflerSpöhrer, U.U.SpöhrerSteidl, I.I.SteidlSzinicz, L.L.SziniczWorek, F.F.WorekOldiges, H.H.Oldiges2022-03-032022-03-031992https://publica.fraunhofer.de/handle/publica/18144910.1007/BF01981499HLö 7 dimethanesulfonate (1-ÄÄÄ4-(aminocarbonyl)pyridinioÜ methoxyÜmethylÜ-2,4-bisÄ(hydroxyimino) methylÜpyridinium dimethansulfonate) is a broad-spectrum reactivator against highly toxic organophosphorus compounds. The compound was synthesized by a new route with the carcinogenic bis(chloromethyl)ether being substituted by the non-mutagenic bis(methylsulfonoxymethyl)ether. The very soluble dimethanesulfonate of obidoxime was also prepared by this way. HLö 7 dimethanesulfonate is the first water-soluble salt of HLö 7 that should be suitable for the wet/dry autoinjector technology, because aqueous solutions of HLö 7 are not very stable (calculated shelf-life 0.2 years when stored at 8 degree C, 1 M solution, pH 2.5).enAcetylcholinesteraseHI 6HLö 7obidoximeorganophosphateoximereactivationSynthesetherapy570610620660571journal article